Galderma reports pediatric Nemluvio data as Galderma stock gains value

Published on 10/19/2026 at 10:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Galderma's phase II study showed itch responses of 56%-72% at Week 16. Galderma stock trades at EUR 188.10 on October 19, 2026.

Nemolizumab data and market context

Galderma announced pediatric phase II data on October 15, 2026, with itch response rates of 56%-72% at Week 16.
First-half 2026 net sales reached USD 3.10 billion, while core EBITDA was USD 802.00 million.
Galderma stock trades at EUR 188.10 at 10:09 a.m. CEST at Lang & Schwarz on October 19, 2026.
Full-year 2026 net sales growth guidance stands at 19%-21% at constant currency.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma (ISIN CH1335392721) announced new pediatric phase II data for nemolizumab on October 15, 2026, while its stock was trading at EUR 188.10 at Lang & Schwarz at 10:09 a.m. CEST on October 19, 2026. The study adds a quantified development update to the company's therapeutic dermatology pipeline.

Pediatric data add to pipeline

According to Galderma, children aged 2 to 11 recorded peak itch response rates of 56%-72% at Week 16 across the study cohorts. Sleep disturbance scores improved by 70%-78% at Week 16, and quality-of-life scores improved by 10.70 to 12.00 points by Week 52.

The company said the findings will be presented at the Pediatric Dermatology Research Alliance Annual Conference. Nemolizumab was well tolerated in the study, with no new safety signals reported in the release.

What does the margin signal mean?

Galderma's first-half 2026 operating figures provide the financial measure for the clinical update. In an earnings-call transcript, Yahoo Finance reported first-half net sales of USD 3.10 billion, up 24.60 percent at constant currency from the prior-year period. Core EBITDA reached USD 802.00 million, up 42.80 percent, and the core EBITDA margin rose to 25.60 percent.

Galderma raised its full-year 2026 net sales growth guidance to 19%-21% at constant currency from 17%-20% previously, while maintaining core EBITDA margin guidance of approximately 26%. The combination of sales growth and margin expansion gives the pediatric program a financial context beyond the clinical result.

Three dated pipeline milestones

On September 21, 2026, Galderma reported its inclusion in the Swiss Market Index and cited 24.60 percent first-half net sales growth. On October 8, 2026, it presented three-year Nemluvio data in patients aged 12 and older. On October 15, 2026, the company reported pediatric phase II data covering patients aged 2 to 11.

Next date and market value

The next explicitly cited reporting date is March 11, 2027, for fourth-quarter 2026 results, according to finanzen.ch. Galderma's market capitalization was CHF 40.4 billion on October 19, 2026, and its 52-week range was CHF 134.90 to CHF 188.25.

Stock price and investor perspective

The clinical update strengthens the evidence base for extending nemolizumab into younger patients, while the financial figures show that growth and profitability are advancing together.

Galderma stock was trading at EUR 188.10 at Lang & Schwarz on October 19, 2026 at 10:09 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Galderma stock.